Canada - English - Health Canada

pfizer canada ulc - pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 9v; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 6b; corynebacterium diphtheriae crm-197 protein - suspension - 2mcg; 2mcg; 2mcg; 2mcg; 2mcg; 2mcg; 4mcg; 20mcg - pneumococcal polysaccharide serotype 4 2mcg; pneumococcal polysaccharide serotype 9v 2mcg; pneumococcal polysaccharide serotype 14 2mcg; pneumococcal polysaccharide serotype 18c 2mcg; pneumococcal polysaccharide serotype 19f 2mcg; pneumococcal polysaccharide serotype 23f 2mcg; pneumococcal polysaccharide serotype 6b 4mcg; corynebacterium diphtheriae crm-197 protein 20mcg - vaccines

Canada - English - Health Canada

glaxosmithkline inc - pneumococcal polysaccharide serotype 1 conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 4 conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 5 conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 6b conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 7f conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 9v conjugated to protein d carrier protein; pneumococcal polysaccharide serotype 14 conjugated to protein d carrier protein; pneumococcal polysacc. serot. 18c conjug. to tetanus toxoid carrier prot.; pneumococcal polysaccharid serot. 19f conjug. to diphtheria toxoid carrier prot.; pneumococcal polysaccharide serotype 23f conjugated to protein d carrier protein - suspension - 1mcg; 3mcg; 1mcg; 1mcg; 1mcg; 1mcg; 1mcg; 3mcg; 3mcg; 1mcg - pneumococcal polysaccharide serotype 1 conjugated to protein d carrier protein 1mcg; pneumococcal polysaccharide serotype 4 conjugated to protein d carrier protein 3mcg; pneumococcal polysaccharide serotype 5 conjugated to protein d carrier protein 1mcg; pneumococcal polysaccharide serotype 6b conjugated to protein d carrier protein 1mcg; pneumococcal polysaccharide serotype 7f conjugated to protein d carrier protein 1mcg; pneumococcal polysaccharide serotype 9v conjugated to protein d carrier protein 1mcg; pneumococcal polysaccharide serotype 14 conjugated to protein d carrier protein 1mcg; pneumococcal polysacc. serot. 18c conjug. to tetanus toxoid carrier prot. 3mcg; pneumococcal polysaccharid serot. 19f conjug. to diphtheria toxoid carrier prot. 3mcg; pneumococcal polysaccharide serotype 23f conjugated to protein d carrier protein 1mcg - vaccines

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - neisseria meningitidis group c capsular polysaccharide protein conjugate - suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - human poliovirus type 3 inactivated; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; diphtheria toxoid; haemophilus influenzae type b polysaccharide protein conjugate - suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - neisseria meningitidis group c strain c11 capsular polysaccharide tetanus toxoid conjugate; haemophilus influenzae type b polysaccharide tetanus toxoid conjugate - powder and solvent for solution for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - neisseria meningitidis group y capsular polysaccharide protein conjugate; neisseria meningitidis group w135 capsular polysaccharide protein conjugate; neisseria meningitidis group a capsular polysaccharide protein conjugate; neisseria meningitidis group c capsular polysaccharide protein conjugate - powder and solvent for solution for injection

United States - English - NLM (National Library of Medicine)

a-s medication solutions - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 54ec0se5pz) (streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:54ec0se5pz), streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 2vf3v7175u) (streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:2vf3v7175u), streptococcus pneumoniae type - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen 2.2 ug in 0.5 ml - in children 6 weeks through 5 years of age (prior to the 6th birthday), prevnar 13® is indicated for: in children 6 years through 17 years of age (prior to the 18th birthday), prevnar 13 is indicated for: risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data on prevnar 13 administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. a developmental toxicity study has been performed in female rabbits administered prevnar 13 prior to mating and during gestation. each dose was approximately 20 times the human dose. this study revealed no evidence of harm to the fetus due to prevnar 13 (see 8.1 data). data animal in a developmental toxicity study, female rabbits were administered prevnar 13 by intramuscular injection twice prior to mating (17 days an

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - measles virus, quantity: 3 tcid50; rubella virus, quantity: 3 tcid50; mumps virus, quantity: 4.3 tcid50; live varicella vaccine, quantity: 3.99 pfu - injection, powder for - excipient ingredients: dibasic sodium phosphate heptahydrate; monobasic sodium phosphate; sodium bicarbonate; albumin; hydrolysed gelatin; sucrose; phenolsulfonphthalein; monobasic potassium phosphate; neomycin; potassium chloride; urea; sorbitol; dibasic potassium phosphate; monosodium glutamate monohydrate; sodium chloride; glucose monohydrate; magnesium sulfate heptahydrate; ferric nitrate nonahydrate; dibasic sodium phosphate dihydrate; sodium pyruvate; folic acid; calcium pantothenate; inositol; choline chloride; nicotinamide; pyridoxine hydrochloride; thiamine hydrochloride; riboflavine; cystine; tyrosine; arginine; glycine; histidine; isoleucine; leucine; lysine; methionine; phenylalanine; threonine; tryptophan; serine; valine; glutamine; calcium chloride dihydrate; water for injections; ascorbic acid; polysorbate 80; dibasic sodium phosphate; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; histidine hydrochloride; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; menadione; nicotinic acid; aminobenzoic acid; pyridoxal hydrochloride; retinol acetate; dl-alpha-tocopheryl phosphate disodium - proquad is indicated for simultaneous immunisation against measles, mumps, rubella and varicella in individuals 12 months through 12 years of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - pneumococcal polysaccharide serotype 14 2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 18c 2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 19f 2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 23f 2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 4 2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 6b 4ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 9v 2ug (conjugated with diphtheria crm 197 protein) - suspension for injection - 0.5 ml - active: pneumococcal polysaccharide serotype 14 2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 18c 2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 19f 2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 23f 2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 4 2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 6b 4ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 9v 2ug (conjugated with diphtheria crm 197 protein) excipient: aluminium phosphate sodium chloride water for injection